N-(2-hydroxypropyl)methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo evaluation.
Ellipticine derivatives have potential as anticancer drugs. Their clinical use has been limited, however, by poor solubility and host toxicity. As N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-anticancer conjugates are showing promise in early clinical trials, a series of novel HPMA copolymer conjugates have been prepared containing the 6-(3-aminopropyl)-ellipticine derivative (APE, NSC176328). Drug was linked to the polymer via GFLG or GG peptide side chains. To optimize biological behavior, HPMA copolymer-GFLG-APE conjugates with different drug loading (total APE: 2.3-7% w/w; free APE: <0.1% w/w) were synthesized. Conjugation of APE to HPMA copolymers considerably increased its aqueous solubility (>10-fold). HPMA copolymer-GG-APE did not liberate drug in the presence of isolated lysosomal enzymes (tritosomes), but HPMA copolymer-GFLG-APE released APE to a maximum of 60% after 5 h. The rate of drug release was influenced by drug loading; lower loading led to greater release. Whereas free APE (35 microg/mL) caused significant hemolysis (50% after 1 h), HPMA copolymer-APE conjugates were not hemolytic up to 300 microg/mL (APE-equiv). As would be expected from its cellular pharmacokinetics, HPMA copolymer-GFLG-APE was >75 times less cytotoxic than free drug (IC(50) approximately 0.4 microg/mL) against B16F10 melanoma in vitro. However, in vivo when tested in mice bearing s.c. B16F10 melanoma, HPMA copolymer-GFLG-APE (1-10 mg/kg single dose, APE-equiv) given i.p. was somewhat more active (highest T/C value of 143%) than free APE (1 mg/kg) (T/C =127%). HPMA copolymer-APE conjugates warrant further evaluation as potential anticancer agents.
Searle
F
F
Centre for Polymer Therapeutics, School of Pharmacy, University of London, 29/39 Brunswick Square, London WC1N 1AX, UK.
Gac-Breton
S
S
Keane
R
R
Dimitrijevic
S
S
Brocchini
S
S
Sausville
E A
EA
Duncan
R
R
D000178:Acrylamides / Q000008:administration & dosage / Q000138:chemical synthesis / Q000493:pharmacokinetics*; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000138:chemical synthesis / Q000493:pharmacokinetics*; D002455:Cell Division / Q000187:drug effects; D004337:Drug Carriers / Q000008:administration & dosage / Q000138:chemical synthesis / Q000493:pharmacokinetics; D004353:Drug Evaluation, Preclinical; D004611:Ellipticines / Q000008:administration & dosage / Q000138:chemical synthesis / Q000493:pharmacokinetics*; D006461:Hemolysis / Q000187:drug effects; D008297:Male; D008689:Methacrylates / Q000008:administration & dosage / Q000138:chemical synthesis / Q000493:pharmacokinetics; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011108:Polymers / Q000008:administration & dosage / Q000138:chemical synthesis / Q000493:pharmacokinetics*; D012995:Solubility; D013810:Therapeutic Equivalency; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000637:transplantation
D000178:Acrylamides; D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D004611:Ellipticines; D008689:Methacrylates; D011108:Polymers; C045985:methacrylamide; C032802:hydroxypropyl methacrylate